Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2006-08-22
2006-08-22
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S185100, C424S093100, C424S093200, C424S093400, C435S252300
Reexamination Certificate
active
07094410
ABSTRACT:
A DNA vaccine effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor protein. This invention provides DNA vaccines that encode VEGF receptor-2 (KDR, SEQ ID NO: 2), VEGF receptor-1 (Flt-1, (SEQ ID NO: 4), or Flk-1 (the murine homolog of KDR, SEQ ID NO: 6), DNA sequences SEQ ID NOS: 1, 3, and 5 respectively, as well as methods of using such a DNA vaccine to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Anti-angiogenesis and subsequent decrease in tumor growth and dissemination is achieved.
REFERENCES:
patent: 5851999 (1998-12-01), Ullrich et al.
patent: 5939400 (1999-08-01), Steinman et al.
patent: 6086891 (2000-07-01), Hurwitz et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 6235523 (2001-05-01), Gajewczyk et al.
patent: WO 02/03961 (2002-01-01), None
Berzofsky, JA et al., “Progress on new vaccine strategies for the immunotherapy and prevention of cancer”, Jun. 2004, J. Clin. Invest. vol. 113: p. 1515-1525.
Restifo, NP et al. “The promise of nucleic acid vaccines”, 2000, Gene Therapy vol. 7: p. 89-92.
Gura, T. “Systems for Identifying New Drugs Are Often Faulty”, Nov. 1997, Science, vol. 278: p. 1041-1042.
Steinman, RM et al., “Immunotherapy: Bewitched, Bothered, and Bewildered No More”, Jul. 2004, Science, vol. 305: p. 197-200.
Ferrara, N. et al. “The biology of VEGF and its receptors”, Jun. 2003, Nat Med., vol. 9: p. 669-676.
Garmory H.S. et al. “Salmonella vaccines for use in humans: present and future perspectives”, Jul. 2002, FEMS Micro. Rev. vol. 26: p. 339-353.
Marshall et al., J. Clin. Oncol. 23(4):720-31 (2005).
Schlom et al., Dev. Biol. (Basel) 116:27-47 (2004).
Shin Sasaki, et al., Nature Biotechnology, vol. 19, pp. 543-547 (Jun. 2001).
Nicholas P Restifo, Nature Biotechnology, vol. 19, pp. 527-528 (Jun. 2001).
Wolfgange W. Leitner, et al., Cancer Research, vol. 60, pp. 51-55 (Jan. 1, 2000).
N.P. Restifo. et al . . . Gene Therapy vol. 7 pp. 89-92 (2000).
Bruce A. Keyt. et al., The Journal of Biological Chemistry, vol. 271, No. 10, pp. 5638-5646 (1996).
Yu-Quan Wei, et al., Nature Medicine, vol. 6, No. 10. pp. 1160-1166 (Oct. 2000).
William Matthews, et al., Proc. Nat'l. Acad. Sci., USA, vol. 88, pp. 9026-9030 (Oct. 1991).
Timothy P. Quinn, et al., Proc. Nat'l. Acad. Sci, USA, vol. 90, pp. 7533-7537 (Aug. 1993).
Rong XIANG, et al., Clinical Cancer Research, vol. 7. pp. 856s-864s (Mar. 2001) (Suppl.).
Andreas G. Niethammer et al Nature Medicine. vol 8 (12). pp 1369-1375 (Dec. 2002).
Niethammer Andreas G.
Reisfeld Ralph A.
Xiang Rong
Burkhart Michael
Olson & Hierl Ltd.
Priebe Scott D.
The Scripps Research Institute
LandOfFree
DNA vaccine against proliferating endothelial cells and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA vaccine against proliferating endothelial cells and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vaccine against proliferating endothelial cells and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3710166